France's Median Technologies reports 2025 revenue up 2.6%, record-high order backlog

Median Technologies SA

19/01/2026 06:13

Overview

France-based AI medical software firm reported 2025 revenue up 2.6% vs 2024 levels

Order backlog at all-time high of €76.6 mln, indicating strong future revenue

Company expects FDA decision for eyonis® LCS in the coming weeks

Outlook

Company expects FDA clearance for eyonis® LCS in coming weeks

Median anticipates CE marking for eyonis® LCS in Q2 2026

Company plans to expand eyonis® portfolio in 2026

Result Drivers

RECORD BOOKINGS - Median reported record iCRO bookings in 2025, contributing to an all-time high order backlog of €76.6 mln

REGULATORY MILESTONES - FDA decision for eyonis® LCS expected soon, with CE marking anticipated in Q2 2026

COMMERCIAL AGREEMENTS - First U.S. and European distribution agreement for eyonis® LCS signed in December 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Slight Beat*
EUR 23.50 mln
EUR 23.40 mln (2 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Median Technologies SA is €9.90, about 128.9% above its January 16 closing price of €4.33

Press Release: ID:nBw2mMLjna

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)